ApoB blood test
Apolipoprotein B. Also called: Apo B, Apolipoprotein B-100, ApoB-100
ApoB counts the particles that can build plaque: each LDL, VLDL remnant and Lp(a) particle carries one ApoB molecule. Labcorp and Quest print below 90 mg/dL as desirable; 130 mg/dL or higher was a risk-enhancing factor in the 2018 AHA/ACC guideline.
An advanced lipid test, ordered with or after a standard Lipid Panel. The panel page explains when each test is ordered.
At a glance
| What it measures | The main protein of LDL, VLDL and its remnants, and Lp(a). Each of these particles carries one ApoB molecule, so ApoB is a particle count. |
|---|---|
| Sample | Serum or plasma. Fasting is not needed. |
| Adult cut-offs | Labcorp: desirable below 90 mg/dL, borderline high 90-99, high 100-130, very high above 130. Quest: optimal below 90, moderate 90-129, high 130 or higher. |
| Peptides that move it | Lowered in trials of Tirzepatide, Retatrutide and Liraglutide; unchanged on Leuprolide and Goserelin. |
| Lab code | LOINC 1884-6 (Labcorp 167015, Quest 91726) |
What is ApoB?
Apolipoprotein B (ApoB) is the structural protein of the particles that carry cholesterol into artery walls: LDL, VLDL and its remnants, and Lp(a). Each particle carries a single ApoB molecule, so the ApoB level is a count of these particles, while LDL cholesterol measures how much cholesterol they hold. The two usually agree. When they do not, risk follows ApoB more closely.
How it is made and regulated
Where it is made
ApoB comes in two forms. ApoB-100 predominates in LDL and VLDL; ApoB-48 is a constant part of chylomicrons, the particles that carry fat from the gut. Kane and colleagues told them apart in 1980. Standard ApoB tests detect both, but ApoB-48 particles are so few, even after a meal, that total ApoB is in practice the count of VLDL, LDL and Lp(a) particles.
What controls it
The liver clears ApoB particles through the LDL receptor. Mutations in the LDL receptor, the APOB gene itself or PCSK9 slow that clearance and cause inherited high cholesterol. Statins, ezetimibe and PCSK9 inhibitors all raise LDL-receptor activity, which speeds the removal of ApoB particles.
How it travels in the blood
Labs measure ApoB with an antibody-based assay: immunologic at Labcorp and immunoturbidimetric at Quest. It is measured directly rather than calculated from other lipids the way most LDL results are.
How long it lasts
Fasting does not change ApoB: the European lipid consensus found ApoB, HDL and Lp(a) unaffected by fasting or non-fasting status, so ApoB can be added to a non-fasting lipid panel.
What it does
In UK Biobank and the FOURIER and IMPROVE-IT trials, ApoB, non-HDL cholesterol and triglycerides each predicted heart attack, but when they were assessed together only ApoB was associated with it (hazard ratio 1.27 per standard deviation).
Sources: [3]
Reference ranges
ApoB is read against risk categories. Labcorp and Quest both print below 90 mg/dL as desirable or optimal; the 2018 AHA/ACC guideline counted 130 mg/dL or higher as a risk-enhancing factor, and the European lipid consensus flags 100 mg/dL or higher as abnormal.
Labcorp (test 167015)
| Group | Range (mg/dL) |
|---|---|
| Desirable | <90 |
| Borderline high | 90-99 |
| High | 100-130 |
| Very high | >130 |
As printed on Labcorp's sample report for test 167015 (a 32-year-old woman). The report adds treatment targets: below 80 mg/dL at very high risk (below 70 at extreme risk) and below 90 at high or moderate risk.
Quest Diagnostics (test 91726)
| Group | Range (mg/dL) |
|---|---|
| Optimal | <90 |
| Moderate | 90-129 |
| High | 130 or higher |
Read from Quest's test directory for the East service area. Quest adds that a treatment target may be below 80 mg/dL or lower, depending on risk.
2018 AHA/ACC guideline; European lipid consensus
| Group | Range (mg/dL) |
|---|---|
| Risk-enhancing factor (2018 AHA/ACC) | 130 or higher |
| Flagged abnormal (European lipid consensus) | 100 or higher |
The 2018 guideline said 130 mg/dL corresponds to an LDL of 160 mg/dL or higher. The European consensus uses its flag on non-fasting and fasting samples alike.
Treatment targets are lower than these cut-offs for people at high risk; use the range on your own report.
Units: Labs outside the US often report ApoB in g/L. Divide mg/dL by 100: 100 mg/dL is 1.00 g/L. [9]
Is there an "optimal" range?
There is no single ApoB target: the cut-off that matters depends on your risk.
Below 90 mg/dL is desirable
<90 mg/dL
Labcorp and Quest reports
Both labs print this as the desirable or optimal range.
130 mg/dL or higher adds to risk
130 mg/dL or higher
2018 AHA/ACC guideline
A risk-enhancing factor, especially with persistently high triglycerides; it favoured starting a statin in borderline-risk adults.
Sources: [11]
Lower targets at higher risk
<80 mg/dL at very high risk; <100 mg/dL at high risk
European targets in the 2016 lipid consensus
ApoB goals set by cardiovascular risk level, alongside LDL and non-HDL cholesterol goals.
Sources: [9]
What raises it
| Factor | How | How much |
|---|---|---|
| Inherited high cholesterol (LDLR, APOB or PCSK9 mutations)Condition | Slower clearance of ApoB particles raises LDL and ApoB from birth. | No published magnitude [5] |
| High triglycerides, type 2 diabetes, obesityCondition | Many small, cholesterol-poor particles can push ApoB up while LDL cholesterol looks normal. | No published magnitude [2] [12] |
What lowers it
| Factor | How | How much |
|---|---|---|
| Statins, ezetimibe and PCSK9 inhibitorsMedication | All raise LDL-receptor activity, so ApoB particles are cleared faster. | No published magnitude [1] |
| Incretin drugsPeptide | Tirzepatide and Retatrutide lowered ApoB in phase 2 diabetes and obesity trials. | -17.4% vs placebo on tirzepatide 15 mg at 26 weeks [13] [14] |
Peptides that affect ApoB
How each peptide in our library changes ApoB, from published trials. None of the FDA labels we checked (GLP-1, tesamorelin, IGF-1 and GnRH drugs) reports ApoB, and many lipid studies report LDL but not ApoB, so every row below comes from a study that measured ApoB itself. No published trial reports ApoB itself after Semaglutide: one open-label trial reports a better ApoB/ApoA1 ratio and the others measured only ApoB-48, the intestinal form. No study has measured ApoB after dosing Tesamorelin, MK-677 (Ibutamoren), Sermorelin, CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin or Lixisenatide; PubMed searches for each with apolipoprotein B find no human ApoB data (the GHRP and hexarelin papers are mouse atherosclerosis studies).
| Peptide | Effect on ApoB | Size of effect | Evidence |
|---|---|---|---|
| Exenatide | Lowers | 211 adults with type 2 diabetes, 30 weeks: ApoB -0.036 g/L from a baseline of 0.81 g/L on once-weekly exenatide; -0.013 g/L, not significant, on the twice-daily formA small fall on the weekly form in one trial with no placebo group. [15] | Human trials |
| IGF-1 (Insulin-Like Growth Factor 1) | Lowers | 10 healthy men, recombinant IGF-1 40 micrograms/kg/day for 7 days: ApoB fell 6.3%One short, small study; the effect of long-term treatment is unknown. [16] | Human trials |
| Liraglutide | Lowers | 10 adults with type 2 diabetes, 6 months of 1.2 mg/day: ApoB-100 0.93 vs 1.09 g/L before treatment. After diet-induced weight loss, ApoB stayed low over 1 year on 1.2 mg (change 0.03 mmol/L, not significant) but rose in controls (0.06 mmol/L)Small studies show lower ApoB on liraglutide; no large trial or label reports it. [17] [18] | Human trials |
| Retatrutide | Lowers | Two phase 2 trials (post hoc): ApoB -21.4% on 8 mg and -17.7% on 12 mg at 36 weeks in type 2 diabetes (placebo 0.2%); -20.2% on 8 mg and -24.2% on 12 mg at 48 weeks in obesity without diabetes (placebo -6.8%)The largest ApoB falls of any peptide here, from two phase 2 trials. [14] | Human trials |
| Tirzepatide | Lowers | Phase 2 trial in type 2 diabetes, 26 weeks (post hoc analysis): ApoB fell 17.4% vs placebo on 15 mg (11.0% on 5 mg, 14.8% on 10 mg)A dose-related fall; no ApoB data from the obesity trials have been published. [13] | Human trials |
| Goserelin | No clear effect | Measured, no change: women treated for endometriosis with goserelin 3.6 mg every 4 weeks for 6 months had no significant ApoB change in a randomized comparison (danazol raised ApoB 29.0%) or in a 15-woman studyTwo endometriosis studies found no ApoB change. [19] [20] | Human trials |
| Leuprolide | No clear effect | Measured, no change: in 26 men with an enlarged prostate on depot leuprolide, ApoB was unchanged while total cholesterol rose 10.6% and triglycerides 26.9%ApoB held steady even though cholesterol and triglycerides rose. [21] | Human trials |
| Dulaglutide | Unclear | Two diabetes trials disagree: ApoB fell 14.1% vs placebo on dulaglutide at 26 weeks in one; in the other it changed +2.1% at 36 weeks on dulaglutide 1.5 mg (placebo 0.2%)Dulaglutide was the comparison drug in both trials, and the results point different ways. [13] [14] | Human trials |
What high or low results can mean
A high result
Above 130 mg/dL is very high on Labcorp reports, and 130 or higher is high on Quest reports and was a risk-enhancing factor in the 2018 AHA/ACC guideline. A high ApoB with a normal LDL means many small, cholesterol-poor particles.
- Inherited high cholesterol
- High triglycerides
- Type 2 diabetes or obesity
Sources: [10] [7] [11] [12] [2]
A low result
Below 90 mg/dL is desirable. On treatment, lower targets apply at higher risk: Labcorp prints below 80 mg/dL for very high risk.
- Cholesterol-lowering treatment
How the test works
| Sample | Serum (preferred) or plasma: 2 mL at Labcorp, 1 mL of serum at Quest. |
|---|---|
| Fasting | Not needed. ApoB is the same fasting and non-fasting. |
| Timing | The 2026 ACC/AHA guideline recommends measuring ApoB selectively, not in everyone: for example with triglycerides above 200 mg/dL, diabetes, or an LDL already below 70 mg/dL on treatment. The 2018 guideline gave triglycerides of 200 mg/dL or higher as a reason to measure it. |
| Lab differences | Antibody-based immunoassay (immunologic at Labcorp, immunoturbidimetric at Quest). US labs report mg/dL; many others report g/L. |
| Retesting | The 2026 ACC/AHA guideline reassesses lipids after starting or changing treatment, looking at both the percentage fall and the level reached. The 2018 guideline it replaced rechecked at 4 to 12 weeks, then every 3 to 12 months as needed. |
| Labcorp order code | 167015: Apolipoprotein B |
| Quest Diagnostics order code | 91726: Cardio IQ Apolipoprotein B |
| LOINC codes |
|
History
ApoB moved from a research measurement to a guideline risk factor as studies showed particle number tracks risk better than particle cholesterol.
- 1980Kane and colleagues separate ApoB-100, the form in LDL and VLDL, from ApoB-48 in chylomicrons. [4]
- 1980Sniderman and colleagues find that ApoB separated people with and without coronary disease better than LDL cholesterol did, and name high ApoB with normal LDL "hyperapobetalipoproteinemia". [12]
- 2018The AHA/ACC cholesterol guideline lists ApoB of 130 mg/dL or higher as a risk-enhancing factor. [11]
- 2026The ACC/AHA dyslipidemia guideline replaces the 2018 guideline and adds ApoB as a selective test when LDL may understate risk. [22] [2]
FAQ
What is a normal ApoB?
Labcorp and Quest print below 90 mg/dL as desirable. Labcorp calls 90-99 borderline high, 100-130 high and above 130 very high; Quest calls 90-129 moderate and 130 or higher high.
Is ApoB better than LDL?
It answers a different question. LDL cholesterol measures how much cholesterol the particles carry; ApoB counts the particles. When the two disagree, risk follows ApoB: in UK Biobank and two large trials, only ApoB stayed linked to heart attack when ApoB, non-HDL cholesterol and triglycerides were assessed together.
What does high ApoB with a normal LDL mean?
That you have more particles than your LDL suggests, each carrying less cholesterol. This is more common with high triglycerides, type 2 diabetes and obesity.
What ApoB level adds to heart risk?
The 2018 AHA/ACC guideline counted 130 mg/dL or higher as a risk-enhancing factor, which corresponds to an LDL of 160 mg/dL or higher. Open summaries of the 2026 ACC/AHA guideline list selected lipid biomarkers among its risk-enhancing factors but give no ApoB cut-off.
Who should get an ApoB test?
The 2026 ACC/AHA guideline does not recommend it for everyone. It is most useful when LDL may understate risk: with triglycerides above 200 mg/dL, diabetes, or an LDL already below 70 mg/dL on treatment.
Sources: [2]
Which peptides lower ApoB?
In phase 2 trials, Tirzepatide 15 mg lowered ApoB 17.4% vs placebo, and Retatrutide lowered it by up to 24.2% (placebo -6.8%). Smaller studies show falls on Liraglutide and weekly Exenatide.
Does semaglutide lower ApoB?
There are no published ApoB results for Semaglutide. One open-label trial reports a better ApoB/ApoA1 ratio, and other studies measured only ApoB-48.
Sources: [23]
Do growth hormone peptides change ApoB?
No study has measured ApoB after Tesamorelin, MK-677 (Ibutamoren), Sermorelin, CJC-1295 or Ipamorelin. A 7-day study of injected IGF-1 (Insulin-Like Growth Factor 1) in 10 healthy men found ApoB fell 6.3%.
Sources: [16]
Do GnRH drugs raise ApoB?
Not in the studies that measured it. ApoB was unchanged on Leuprolide in men even though cholesterol rose, and unchanged on Goserelin in women treated for endometriosis.
References
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. PMID 31642874
- Sabouret P, Mafrica D, Giamundo DM, et al. The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management. Life (Basel). 2026;16(9). PMID 42795336
- Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022;7(3):250-256. PMID 34773460
- Kane JP, Hardman DA, Paulus HE. Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. Proc Natl Acad Sci U S A. 1980;77(5):2465-9. PMID 6930644
- Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-6. PMID 12730697
- Labcorp. Test 167015: Apolipoprotein B. Methodology, specimen, risk categories and LOINC map. labcorp.com/tests/167015/apolipoprotein-b
- Quest Diagnostics. Test 91726: Cardio IQ Apolipoprotein B. Test directory: methodology, specimen, LOINC and risk categories. testdirectory.questdiagnostics.com/test/test-detail/91726/cardio-iq-apolipoprotein-b?cc=PHP
- Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540-548. PMID 32101259
- Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944-58. PMID 27122601
- Labcorp. Sample report, test 167015 (Apolipoprotein B): risk categories and therapeutic targets as printed for a 32-year-old woman (reported 05/20/2019). files.labcorp.com/testmenu-d8/sample_reports/167015.pdf
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. PMID 30586774
- Sniderman A, Shapiro S, Marpole D, et al. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. Proc Natl Acad Sci U S A. 1980;77(1):604-8. PMID 6928647
- Wilson JM, Nikooienejad A, Robins DA, et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22(12):2451-2459. PMID 33462955
- Ruotolo G, Harris C, Lin Y, et al. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes Obes Metab. 2026;28(11):10183-10194. PMID 42608321
- Chiquette E, Toth PP, Ramirez G, et al. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag. 2012;8:621-9. PMID 23166441
- Oscarsson J, Lundstam U, Gustafsson B, et al. Recombinant human insulin-like growth factor-I decreases serum lipoprotein(a) concentrations in normal adult men. Clin Endocrinol (Oxf). 1995;42(6):673-6. PMID 7634511
- Vergès B, Duvillard L, Pais de Barros JP, et al. Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression. Diabetes Care. 2021;44(4):1027-1037. PMID 33531418
- Engelbrechtsen L, Lundgren J, Wewer Albrechtsen NJ, et al. Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. Obes Sci Pract. 2017;3(4):425-433. PMID 29259801
- Lemay A, Brideau NA, Forest JC, et al. Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol. Clin Endocrinol (Oxf). 1991;35(4):305-10. PMID 1836425
- Anastasilakis AD, Polyzos SA, Vorkas PA, et al. Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study. J Clin Med. 2023;12(16). PMID 37629472
- Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol. 1995;154(1):100-4. PMID 7539852
- Writing Committee Members, Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. PMID 41824552
- Kimura T, Katakura Y, Shimoda M, et al. Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study). Diabetes Obes Metab. 2023;25(12):3632-3647. PMID 37646192
Educational information, not medical advice. Lab ranges and test codes were checked on November 2, 2026. Always use the range printed on your own report, and talk to a clinician about your results.